Paris, March 3, 2011 – BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated
to the supportive care and treatment of cancer patients, today announced the award of
€2 million in funding over 30 months from the « Fond Unique Interministériel » (a French
program supporting collaborative research projects) including an amount of €743,000
specifically allocated to BioAlliance Pharma. This program aims at establishing the proof of
concept for the administration by mucosal route of biological products. The first application is
a peptide benefiting from the delivery properties of the Lauriad™ mucoadhesive technology.
This program will also permit to test the Lauriad™ technology in the veterinary area.
This collaborative program, co-labelled by both « Clusters of excellence » Medicen Paris
Region and Atlanpôle, aims at designing a flu vaccine administered by mucosal route.
The consortium is led by BioAlliance Pharma and involves several academic centers and
- The « Laboratoire de Virologie et Pathologies Humaines VirPath » (Lyon), headed by
Pr. Bruno Lina, National flu reference center.
- The « Laboratoire EA 401 Matériaux et Produits de Santé », headed by Pr. Pierre
Tchoreloff from Paris XI University, specialized in optimization of peptide
- Sogeval, a French veterinary drug company, which develops, produces, and markets
veterinary products. It has developed a range of pet drugs, particularly in infectiology.
The involvement of Sogeval could open the path to new opportunities for the
Lauriad™ muco-adhesive technology in the veterinary area.
- Gredeco, founded by Pr. Lofti Ben Slama (Paris), will be in charge of the studies on
peptide mucous penetration.
- Pr Pierre Dellamonica’s team, from Nice University Hospital, worldwide known for its
expertise in infectiology, will be in charge of immunological assessment prior to entry
into clinical phase.
« This program is capitalizing on the Lauriad™ patented mucoadhesive technology, already
validated with chemical molecules for Loramyc® and Sitavir®. This substantial public grant will
open the path to new application fields with complex biological products and new potential
markets”, stated Dominique Costantini, CEO of BioAlliance Pharma.
About BioAlliance Pharma
Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients – BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries, in Korea and in the United States
Setofilm® (prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Sitavir® (Acyclovir Lauriad TM) (labialis herpes): Positive phase III final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results
AMEP® (invasive melanoma): Phase I
Clonidine LauriadTM (mucositis): Phase II
Doxorubicin Transdrug® (liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and
its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA
is providing this communication as of this date and does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of
BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the
AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59